AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05607641 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ketorolac tromethamine, solution for injection then Neospastil, film-coated tablets
Description: These medicines were used for patients of Group 1 (phase II) and Group 4 (phase III).~Stage 1 (1st day of study treatment) - Ketorolac tromethamine, solution for injection, 1 ml every 8 hours.~Stage 2 (2nd day of study treatment) - Neospastil, film-coated tablets, 1 tablet every 6 hours.~Stage 3 (3rd-5th days of study treatment) - Neospastil, film-coated tablets, 1 tablet on demand with an interval of at least 6 hours, not more than 4 tablets per day.
Study NCT05607641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac tromethamine, solution for injection then Ketorolac tromethamine, coated tablets
Description: These medicines were used for patients of Group 2 (phase II) and Group 5 (phase III).~Stage 1 (1st day of study treatment) - Ketorolac tromethamine, solution for injection, 1 ml every 8 hours.~Stage 2 (2nd day of study treatment) - Ketorolac tromethamine, coated tablets, 1 tablet every 6 hours.~Stage 3 (3rd-5th days of study treatment) - Ketorolac tromethamine, coated tablets, 1 tablet on demand with an interval of at least 6 hours, not more than 4 tablets per day.
Study NCT05607641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neospastil, solution for injection then Neospastil, film-coated tablets
Description: These medicines were used for patients of Group 3 (phase II) and Group 6 (phase III).~Stage 1 (1st day of study treatment) - Neospastil, solution for injection, 2 ml every 8 hours.~Stage 2 (2nd day of study treatment) - Neospastil, film-coated tablets, 1 tablet every 6 hours.~Stage 3 (3rd-5th days of study treatment) - Neospastil, film-coated tablets, on demand 1 tablet with an interval of at least 6 hours, not more than 4 tablets per day.
Study NCT06189547 — intervention group
Intervention type: OTHER
Intervention: different prior cancer history type
Description: different types of prior cancer history
Study NCT05030558 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-assisted patient education intervention designed according to the common-sense model
Description: Implementation of patient education with the website created about fibromyalgia disease in 4 weeks according to the disease perception themes reached as a result of the qualitative research.
Study NCT05030558 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The website where the Turkish Physical Medicine and Rehabilitation Association Fibromyalgia patient booklet is available as pdf.
Description: The website where the Turkish Physical Medicine and Rehabilitation Association Fibromyalgia patient booklet is available as pdf.
Study NCT05763797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation Exercise
Description: Group 1, participant will be in a supportive care program with other Black cancer patients in which you will practice meditation.~Group 2, participate will be in a supportive care program with other Black cancer patients that focuses on coping with cancer.~Participants will be asked to participate weekly sessions for 4 weeks (that is a total of 4 sessions) and each session will last about 60 minutes. Both groups will be delivered via Zoom (a web-based videoconferencing service) and led by a master's-level interventionist.
Study NCT04240054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib (1.5 mg/m\^2) subcutaneous on days 1, 8 and 15
Study NCT04240054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Isatuximab (10 mg/kg) IV on days 1, 8, 15 and 22
Study NCT04240054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (250 mg/m\^2) IV on days 1, 8 and 15
Study NCT04775186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Burch colposuspension and Mid-urethral slings (TVT and TOT)
Description: Laparoscopic Burch colposuspension and Mid-urethral slings (TVT and TOT)
Study NCT05109806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: problem prevention therapy with CHD
Description: The psychological exercises are based on the evidence-based Fun FRIENDS protocol (Burhanar, 2016) for reducing emotional behavioral issues. Separate workshop of adolescents will be designed based on transition in child cardiology to adult cardiology(Moons et al., 2009) . A cardiologist and psychologist will psycho educate them about self-care, needs of transition period and strength and strains about further life.
Study NCT05109806 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: problem prevention therapy with CHD
Description: The psychological exercises are based on the evidence-based Fun FRIENDS protocol (Burhanar, 2016) for reducing emotional behavioral issues. Separate workshop of adolescents will be designed based on transition in child cardiology to adult cardiology(Moons et al., 2009) . A cardiologist and psychologist will psycho educate them about self-care, needs of transition period and strength and strains about further life.
Study NCT04896814 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation
Description: The participant will be placed in the supine position with the soles of the feet together and the knees flexed and abducted at 90º. Two adhesive electrodes will be used for each leg. First one: 32 mm of diameter that will be placed in the posterior tibial nerve, that is, 4-5 cm cranial to the internal malleolus, between the posterior edge of the medial border of the tibia and the soleus tendon. Second one: 50x50 mm to be placed in the ipsilateral calcaneus. The electrodes will be connected to the NeuroTracTM PelviTone stimulation device. The stimulation range will be selected according to the tolerable pain limit for the patient, between 0.5 and 20 mA (adjustable in 1 mA levels).The intensity elevation will be allowed each time the patient perceives the fading of the previous sensation due to accommodation. Under no circumstances should the stimulation cause a painful feeling.
Study NCT04896814 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participant will be placed in the same position. Two 50 x 50 mm adhesive electrodes will be placed on the external face of the thigh, on a single leg. This area is outside the territory of the posterior tibial nerve. A discontinuous current at 2Hz frequency and a pulsed frequency of 50 µs, with 2 seconds of work and 10 seconds of pause will be applied. This simulated current being considered to be insufficient to achieve therapeutic effects in the body and to be outside of the usual ranges described in electrotherapy manuals regarding pain management. The intensity will be selected according to the paint limit level of the patient, between 0.5 and 60 mA (adjustable in 0.1 mA levels), where a low or moderate sensation of the patient will be sought, without muscle contraction.
Study NCT04240054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20 mg PO or IV (10 mg if >75 years) on days 1, 2, 8, 9, 15, 16, 22 and 23
Study NCT05912348 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Low physical Activity Control
Description: Young men and women will transition into a low physically active lifestyle for 10 days.
Study NCT05912348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Physical Activity and Added Carbohydrate Group
Description: Young men and women will transition into a high physically active lifestyle for 10 days and consume added sugar-sweetened beverages. The intervention group will be compared to two control groups and one experimental group.
Study NCT01674816 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repeated Measurements of Knee Alignment and Kinematics
Description: Repeated Measurements of Knee Alignment and Kinematics using tools developed by Eiffel Medtech Inc.
Study NCT01674816 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Computer Guidance of Surgical Actions
Description: Computer Guidance of Surgical Actions using tools developed by Eiffel Medtech Inc.
Study NCT06262594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lemborexant
Description: Drug is administered
Study NCT06262594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lemborexant
Description: Drug is administered
Study NCT04729309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [12C] RO7049389
Description: Participants will receive oral \[12C\] RO7049389.
Study NCT04729309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [13C] RO7049389
Description: Participants will receive IV \[13C\] RO7049389.
Study NCT06262594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Drug is administered
Study NCT06262594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug is administered
Study NCT05065268 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immersive Virtual-Reality Stimulation
Description: IVR stimulation every 2 days (± 1 day) at any time during the day (delivery).
Study NCT05097170 — intervention group
Intervention type: PROCEDURE
Intervention: NIRS during ventricular tachycardia ablation
Description: NIRS: Near-infrared spectroscopy is a measurement technique that non-invasively and continuously monitors the balance between cerebral oxygen consumption and delivery.~BIS: BIS is an electroencephalogram-derived parameter developed to monitor the hypnotic effects of anesthesia.
Study NCT05610241 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression Therapy System Prototype
Description: A device designed to deliver compression therapy at a pre-set level to the lower leg for legs with a circumference between 30-50 cm. The device provides compression through a series of three air bladders and is controlled by a battery-powered electronic module that controls compression levels by monitoring bladder pressure.
Study NCT05610241 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Compression
Description: Coban 2 represents the standard of care 2-layer compression wrap used to treat venous leg ulcers. The device consists of a comfort layer and a compression layer. A clinician applies the device to establish compression therapy.
Study NCT05240612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MT-3921
Description: Solution for infusion; Intravenous (IV)
Study NCT05240612 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for infusion; Intravenous (IV)
Study NCT04729309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] RO7049389
Description: Participants will receive an oral suspension of \[14C\] RO7049389.
Study NCT05597137 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc Gluconate
Description: Each participant should receive a regular zinc diet for weeks 1-2 and take zinc supplements for weeks 3-4.
Study NCT05753202 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial current direct stimulation
Description: Transcranial electrical stimulation over two different brain regions associated with cognitive training. 15 sesions in 3 weeks (5 days/week)
Study NCT04586075 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Trio Whole Genome Sequencing and Participant-Specific Research
Description: The initial evaluation begins with short-read genome sequencing of DNA extracted from blood of affected individual(s) and participating family members (The most common approach will be trio whole genome sequencing, which involves the affected child + their parents).~Additional evaluation may include: functional assessments, animal modeling, reverse phenotyping (may require an interim visit), epigenetic profiling, or clinical database matching through selective sharing of coded patient data with external collaborators (e.g., via Matchmaker Exchange and Phenome Central), long read genome sequencing, de novo genome assembly, RNA sequencing, and novel bioinformatics analyses
Study NCT05178290 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHILD back-to-ECE COVID-19 saliva testing
Description: Preschool children and their parent will complete saliva COVID-19 tests at the start of the school year and after winter break as part of a back-to-ECE safely intervention. Tests may be completed during pick up, at drop off, or during school, depending on local on-campus regulations.
Study NCT05178290 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: CHILD back-to-ECE COVID-19 saliva testing
Description: Preschool children and their parent will complete saliva COVID-19 tests at the start of the school year and after winter break as part of a back-to-ECE safely intervention. Tests may be completed during pick up, at drop off, or during school, depending on local on-campus regulations.
Study NCT05178290 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ECE personnel back-to-ECE COVID-19 saliva screening
Description: ECE personnel will complete saliva COVID-19 tests biweekly through the school year as part of a back-to-ECE safely intervention. Tests may be completed on the ECE campus or in the parking lot, depending on local on-campus regulations
Study NCT05178290 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: ECE personnel back-to-ECE COVID-19 saliva screening
Description: ECE personnel will complete saliva COVID-19 tests biweekly through the school year as part of a back-to-ECE safely intervention. Tests may be completed on the ECE campus or in the parking lot, depending on local on-campus regulations
Study NCT05178290 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAGE garden programming
Description: The SAGE garden programming includes installation of a garden; teacher training via Zoom and/or short videos, a binder and website support along with other accompanying materials and teacher technical support (email, text, phone); gardening supplies and gear (e.g., hats, watering cans, gloves); and delivers active songs, games, science experiments and other outdoor learning opportunities.
Study NCT04809025 — intervention group
Intervention type: DEVICE
Intervention: endoscopy
Description: gastroscope
Study NCT04809025 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: radical gastrectomy
Study NCT06181227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVD-104
Description: An intravitreal injection of 50 microliters at the doses described will be given. Visual acuity, optical coherence tomography thickness and vascular perfusion will be evaluated for an effect of the drug.
Study NCT05108441 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound and magnetic resonance imaging measurements of quadriceps femoris
Description: In sedated critically ill children, quadriceps femoris thickness and cross sectional area will be measured with thigh bedside ultrasound, performed by two trained operators consecutively. These two measurements will also be made at the exact same location on a magnetic resonance imaging transverse view of the thigh, to allow comparing them to ultrasound measurements.
Study NCT05757024 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high power laser therapy
Description: m6 laser therapy of ASA company with multilocked wave system and synchronized emission wave lengths 808 and 905 wave lengths
Study NCT05757024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high power laser therapy
Description: m6 laser therapy of ASA company with multilocked wave system and synchronized emission wave lengths 808 and 905 wave lengths
Study NCT05287204 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Musculoskeletal ultrasound
Description: Ultrasound of rectus femoris to determine cross-sectional area, muscle thickness, echo intensity.
Study NCT05287204 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessments of muscle strength and physical function
Description: A battery of tests of physical function and muscle strength (see outcomes section for details).
Study NCT05287204 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolomics
Description: Using metabolomic analysis, concentrations of amino acids and other important analytes will be measured in patient plasma and CRRT effluent
Study NCT05904314 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulation training in electronic fetal monitor management
Description: Simulation training in electronic fetal monitor management
Study NCT06245824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) with pyrotinib
Description: T-DXd, 5.4mg/kg IV day 1 of a 21-day cycle. Pyrotinib, 400mg or 320mg, orally once a day, daily of a 21-day cycle.
Study NCT04897594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TERN-201
Description: Investigational drug
Study NCT05935111 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Self-efficacy (PAS) intervention
Description: The PAS intervention will be a web-based intervention to address the unique barriers to physical activity in adults with obesity, based on self-efficacy theory and effective behavioral change techniques. Self-efficacy is specified as a mediating psychological variable in the conceptual model for the promotion of physical activity. Self-efficacy refers to domain-specific beliefs (e.g., job-, transport-, domestic-, leisure-related physical activity) about their ability to execute differing levels of performance given situational demands. There is a rich literature on the importance of targeting self-efficacy as a modifiable mediating variable in PA-promoting interventions. Also, the PAS intervention will consist of effective behavioral change techniques (e.g., action planning, teach to use prompts/cues, goal setting, etc.).
Study NCT04730349 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT04730349 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: Specified dose on specified days
Study NCT05055362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Honey Spice Group
Description: Consume baked good daily for 10 days and provide samples of saliva, urine and dietary habits and spice intake.
Study NCT05145179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-705
Description: 0.1, 1, 3, 6, 10, 15 or 20mg/kg, IV, Day 1, 8, 15 of each treatment cycle, up to disease progression or intolerable toxicity, death, early withdrawal from the study or loss to follow-up, withdrawal of consent, or the end of the treatment period, whichever occurs first. Every 4 weeks a treatment cycle.
Study NCT04897594 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT04901104 — intervention group
Intervention type: DRUG
Intervention: Thymosin Alpha1
Description: Drug interventions have been done in previous clinical studies
Study NCT02324712 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture using standard stainless steel acupuncture needles inserted into intramuscular tissue for 20 minutes
Study NCT02324712 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Acupuncture using non-penetrating Park Sham Needles for 20 minutes
Study NCT06454162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Ketogenic Diet
Description: the patients will receive KD after nutritional counseling, patients will instructed to start by limiting carbohydrate intake to just 20 g/day for 4 weeks in order to establish ketosis. Then, patients increase their carbohydrate intake by 5 g each week until they reach their individual maximum (approximately 40 g) to maintain stable ketosis. All carbohydrates relevant for elevating blood glucose are limited to 40-50 g/ day. In addition, the glycemic index and glycemic load of carbohydrates have to be below 50 and 60, respectively. This ketogenic diet is equivalent to a traditional ketogenic diet, but with a liberalized macronutrient composition of 70-80% fats, 15-20% proteins and 5-10% carbohydrates (compared to a traditional ketogenic diet with 90% fat, 6% proteins and 4% carbohydrates)+ exercise program
Study NCT06454162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise program
Description: the patients will receive exercise program in the form of aerobic training (10-30 minutes at moderate intensity) and resistance training (1-3 sets of 8-15 repetition maximum (RM)
Study NCT06454162 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise program
Description: the patients will receive exercise program in the form of aerobic training (10-30 minutes at moderate intensity) and resistance training (1-3 sets of 8-15 repetition maximum (RM)
Study NCT05038787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3473329
Description: Administered orally.
Study NCT05038787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study NCT06360497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mindfulness meditation intervention and loving-kindness and compassion meditation intervention
Description: Interventions were conducted by two teachers separately. Mindfulness meditation group provided the knowledge and practice related with mindfulness, and loving-kindness and compassion meditation group provided knowledge and practice related with loving-kindness and compassion meditation.